A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)
Status: Active, not recruiting,
Condition Summary: Age Related Macular Degeneration; Choroidal Neovascular Membrane (Disorder); Subfoveal Neovascular Age-Related Macular Degeneration; Macular Degeneration; Wet Age-Related Macular Degeneration